vimarsana.com

Page 4 - நம்பகத்தன்மை வாழ்க்கை அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Reliance raises oxygen supply to over 700 tonnes a day to Covid-hit states

Billionaire Mukesh Ambani s Reliance Industries Ltd has tweaked manufacturing at its Jamnagar oil refineries to produce over 700 tonnes a day of medical-grade oxygen which is being supplied free of cost to states badly affected by COVID-19, sources said. The company s Jamnagar refineries in Gujarat initially produced 100 tonnes of medical-grade oxygen, which has quickly been ramped up to over 700 tonnes, people aware of the matter said. The supplies being made to states like Gujarat, Maharashtra and Madhya Pradesh will provide relief to over 70,000 critically ill patients everyday. The company plans to raise medical-grade oxygen production capacity to 1,000 tonnes, sources said, without giving a timeline.

The vaccine crisis

The vaccine crisis
indiatoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatoday.in Daily Mail and Mail on Sunday newspapers.

Rituximab Biosimilars Market Players Are Collaborating With Each Other For Innovations In Product Development

Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 The Business Research Company’s Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 LONDON, GREATER LONDON, UK, April 7, 2021 /EINPresswire.com/ Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports The companies operating in the biosimilars industry are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships is shaping the rituximab biosimilars market. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche s Rituxan (rit

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.